Tamoxifen, the first SERM, is an ERα antagonist that competitively inhibits estrogen binding to ERα and was approved by the FDA in 1972 for both pre- and postmenopausal BC patients (18, 19). The gene discussed is ESR1; the disease is breast cancer.